Clinical trial NCT05226390: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
Official title: Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized Adults - Phase I Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: COVID-19 Vaccines
Keywords: MVA-SARS-COV-2
MVA-SARS-2-ST
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
Collaborators: name: German Center for Infection Research
name: IDT Biologika
name: Universitätsklinikum Hamburg-Eppendorf
First posted: 2022-02-07
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This will be a phase I, single-center trial, including a total of 30 participants in two cohorts.

Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen.

Cohort 2 (n=24): Healthy male or female adults aged 18 - ≤ 60 primary immunized with two vaccinations with any regimen using any EU marketed SARS-CoV-2 vaccine (mRNA-, vector-, protein-based, attenuated SARS-CoV-2 virus) or with a single application of COVID-19 Vaccine Janssen and subsequently booster immunized with any EU marketed mRNA vaccine

Both cohorts will be assigned to inhaled vaccination with MVA-SARS-2-ST


Eligibility criteria: Inclusion Criteria:

The subject must not be enrolled before all inclusion criteria (including test results) are confirmed. Subjects meeting all of the criteria listed below will be included in the study.

1. Signed written informed consent from subject prior to any study-related procedure and willingness to comply with treatment and follow-up procedures
2. Healthy men or women, aged ≥ 18 ≤ 60 at day of inclusion having received either

   1. primary immunization (cohort 1) with any regimen using any EU marketed SARS- CoV-2 vaccine or
   2. subsequently booster immunization (cohort 2) with any EU marketed mRNA vaccine

   at least 3 months prior to enrollment
3. Adults with SARS-CoV-2 specific IgG concentration between 10 RU/ml and 1200 RU/ml determined by Anti-SARS-CoV-2-QuantiVac-ELISA (IgG)
4. Males or non-pregnant, non-lactating females of child-bearing potential with negative pregnancy test at screening who agree to comply with the applicable contraceptive requirements of the protocol (Section 3.4) from at least 14 days prior to vaccination and during the entire duration of the study.

   or

   Females without child-bearing potential defined as follows:
   * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or
   * hysterectomy or uterine agenesis or
   * ≥ 50 years and in postmenopausal state \> 1 year or
   * \< 50 years and in postmenopausal state \> 1 year with serum FSH \> 40 IU/l and serum estrogen \< 30 ng/l or a negative estrogen test, both at screening
5. Normal pulmonary function: FEV1 predicted ≥ 80% and FEV1/FVC \> 70%
6. Body mass index 18.5 - 30.0 kg/m2 and weight \> 50 kg at screening
7. Subject is capable of understanding the investigational nature, potential risks and benefits of the clinical trial

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria are met at screening or on dosing day.

1. Previous MVA or rMVA vaccination
2. Known allergy to the components of the SARS-CoV-2 vaccine product as chicken proteins or history of life-threatening reactions to vaccine containing the same substances
3. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine
4. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance; safety laboratory screening evaluation can be repeated a maximum of two times
5. Any finding in the medical history and physical examination deviating from normal and assessed as clinically relevant by the investigator
6. Evidence in the subject's medical history or in the medical examination that might influence the absorption, distribution, metabolism or excretion of the investigational medicinal product
7. Current smoking/ vaping or smoking /vaping in the previous year.
8. Clinically relevant findings in ECG
9. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes
10. Asthma, chronic obstructive pulmonary disease or other lung disease
11. Respiratory tract infection in the 4 weeks prior to study treatment
12. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child
13. Known intolerance to medication used during bronchoscopy, i.e. midazolam and lidocaine.
14. Treatment with ß-adrenoceptor antagonists
15. Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)
16. Drug abuse or positive drug screening
17. Any positive result for HIV1/2, HCV antibody or HBs antigen testing
18. Moderate or severe illness and/or fever \>38 °C within 1 week prior to vaccination
19. History of blood donation within 60 days of enrollment or plans to donate within the treatment phase
20. Participation in a clinical trial or use of an investigational product within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study
21. Investigator or employee of the study site or Sponsor with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, natural or adopted child) of the investigator or employee with direct involvement in the proposed study

Primary outcomes:
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 0
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 1
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 2
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 3
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 4
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 5
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 6
measure: The nature, frequency and severity of adverse events associated with MVA-SARS-2-ST
timeFrame: day 7
measure: Change from baseline of pulmonary function associated with MVA-SARS-2-ST
timeFrame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
measure: Change from baseline of pulmonary function associated with MVA-SARS-2-ST
timeFrame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
measure: Change from baseline of pulmonary function associated with MVA-SARS-2-ST
timeFrame: day 0 (2h), day 1, 3, 7, 14, 28, 56, 140
measure: Change from baseline of pulmonary function associated with MVA-SARS-2-ST
timeFrame: day 0 and twice daily on days 1, 2, 3, 4, 5, 6, 7
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 0
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 1
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 2
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 3
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 4
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 5
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 6
measure: Occurrence of solicited systemic reactogenicity signs and symptoms associated with MVA-SARS-2-ST
timeFrame: day 7
measure: Occurrence of unsolicited adverse events (AE) associated with MVA-SARS-2-ST
timeFrame: from day 0 to day 28 after vaccination
measure: Change of safety laboratory measures associated with MVA-SARS-2-S
timeFrame: day 1, 3, 7, 14, 28, 56, 140
measure: Occurrence of serious adverse events (SAE) associated with MVA-SARS-2-ST
timeFrame: through study completion, an average of 5 month
Secondary outcomes:
measure: To evaluate immunogenicity of the candidate MVA-SARS-2-ST
timeFrame: day 7, 14, 28, 56 and 140
measure: To evaluate immunogenicity of the candidate MVA-SARS-2-ST
timeFrame: day 14
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Hannover Medical School ZKS - Early Clinical Trial Unit at CRC Hannover
Study officials:
affiliation: Hannover Medical School, Department of Respiratory Medicine and Fraunhofer ITEM, Division of Clinical Airway Research
name: Jens Hohlfeld, Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hannover Medical School Institute of Immunology
name: Reinhold Förster, Prof.
role: STUDY_CHAIR
References: